NPI: 1659647808 · FRESNO, CA 93720 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/31/2012
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/31/2012 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 21,473 | $318K |
| 2019 | 16,585 | $485K |
| 2020 | 14,867 | $466K |
| 2021 | 10,666 | $599K |
| 2022 | 10,383 | $567K |
| 2023 | 21,301 | $663K |
| 2024 | 18,654 | $998K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 59,307 | 5,691 | $4.05M |
| 0250 | 5,729 | 391 | $23K | |
| A4657 | Syringe, with or without needle, each | 13,246 | 2,549 | $23K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 15,230 | 1,309 | $165.06 |
| 82728 | 241 | 226 | $12.88 | |
| G0008 | Administration of influenza virus vaccine | 196 | 189 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 8,736 | 823 | $0.00 |
| 90940 | 108 | 105 | $0.00 | |
| 90674 | 106 | 99 | $0.00 | |
| 83550 | 118 | 110 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 82 | 40 | $0.00 |
| 85045 | 562 | 501 | $0.00 | |
| 85041 | 683 | 647 | $0.00 | |
| 83970 | 621 | 551 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 5,925 | 1,761 | $0.00 |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 1,438 | 940 | $0.00 |
| 83540 | 292 | 260 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 560 | 62 | $0.00 |
| 85048 | 682 | 643 | $0.00 | |
| 90661 | 19 | 19 | $0.00 | |
| 90662 | 48 | 47 | $0.00 |